Information Provided By:
Fly News Breaks for May 6, 2019
ESPR
May 6, 2019 | 08:44 EDT
Jefferies analyst Michael Yee believes the FDA's communication to Esperion Therapeutic that it does not plan to host an advisory panel removes a bear argument. The analyst is surprised by the news and keeps a Buy rating on the shares with an $85 price target.
News For ESPR From the Last 2 Days
ESPR
Mar 28, 2024 | 10:59 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
ESPR
Mar 27, 2024 | 10:47 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here